ReviewPituitary2015
Screening for Cushing's syndrome: is it worthwhile?
Review in Pituitary, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Who and how to screen for Cushing's syndrome: the position statement of the Italian Society of Endocrinology.Journal of endocrinological investigation · 2026Guideline
- Traditional Chinese Medicine in Cushing's Syndrome: A Narrative Review of Pathophysiology and Potential Therapeutic Effects.OncoTargets and therapy · 2026Review
- A Bibliometric Analysis and Visualization of the Current Status and Future Perspectives of Adrenal Cortical Adenoma.Cureus · 2025Review
- Leukocytosis in Cushing's syndrome persists post-surgical remission and could predict a lower remission prognosis in patients with Cushing's disease.Journal of endocrinological investigation · 2025Article
- Who and how to screen for endogenous hypercortisolism in a high-risk population: a special issue of the journal of endocrinological investigations.Journal of endocrinological investigation · 2025Article
- Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesity.Journal of endocrinological investigation · 2025Review
- Screening for endogenous hypercortisolism in patients with osteoporosis and fractures: why, when and how.Journal of endocrinological investigation · 2025Review
- Cushing's syndrome screening with the 1-mg dexamethasone suppression test in metabolically healthy and unhealthy obesity phenotypes.International journal of obesity (2005) · 2024Article
- Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited.The Journal of clinical endocrinology and metabolism · 2022Article
- The promising role of risk scoring system for Cushing syndrome: Time to reconsider current screening recommendations.Frontiers in endocrinology · 2022Review
- Second-Line Tests in the Diagnosis of Adrenocorticotropic Hormone-Dependent Hypercortisolism.Annals of laboratory medicine · 2021Review
- A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score.Frontiers in endocrinology · 2021Article
- Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation.Journal of endocrinological investigation · 2020Article
- Toward a Diagnostic Score in Cushing's Syndrome.Frontiers in endocrinology · 2019Review
- Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2018Review
- Association between Higher Serum Cortisol Levels and Decreased Insulin Secretion in a General Population.PloS one · 2016Article
- OPTIMIZING DIAGNOSTIC ACCURACY IN CUSHING SYNDROME USING 1 MG DEXAMETHASONE SUPPRESSION TEST CUT-OFFS.Acta endocrinologica (Bucharest, Romania : 2005)Article
- An update on polycystic ovary syndrome: A review of the current state of knowledge in diagnosis, genetic etiology, and emerging treatment options.Women's health (London, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCushing's syndrome (CS) is a rare disease characterized by a collection of signs and symptoms, also common in the general population without elevated cortisol secretion. During the last years more patients with CS are identified earlier and with milder disease. Many of these patients are diagnosed during screening efforts performed for certain or isolated complaints like weight gain, diabetes mellitus (DM), hypertension, osteoporosis, elevated white blood cell counts and more.
methodsIn this review article the most popular screening test performed in the studies cited was the 1-mg dexamethasone suppression test.
conclusionsCushing is not frequent enough to support the use of routine screening in patients with morbid obesity and type 2 DM. Also only 1% of hypertensive patients have secondary hypertension due to CS. However, screening should be considered in young patients with resistant DM and/or hypertension. Among patients with osteoporosis and vertebral fractures up to 5% were diagnosed with subclinical hypercortisolism; most of these had adrenal adenoma. Screening for CS is important in subjects with adrenal incidentaloma, and many studies show a high prevalence (~10%) of Cushing or subclinical CS in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.